[Anti-influenza effect of bacterial RNAse and the pharmacokinetic basis of its administration in experimental studies].
Anti-influenzal action of bacterial and pancreatic RNAases was studied. It was shown in ovo that the RNAases had distinct virus inhibiting activity with respect to various strains of the grippe A virus and did not practically differ by their activity from remantadin but unlike it had inhibitory action on the grippe B virus. The anti-influenzal activity of bacterial RNAase in contrast to pancreatic one was detected not only in experiments with developing chick embryos but also in albino mice with lethal influenzal infection. The index of the animal protection by the preparation amounted to 54-90 per cent depending on the virus infecting dose and RNAase administration route, the lifespan of the animals being increased by 2.4 to 3.8 days. It was shown that the anti-influenzal effect of bacterial RNAase correlated with high levels of the exogenic enzyme in blood of the animals after the preparation intravenous administration. Elimination of RNAase was observed already within the first 4 hours after the experiment start. Intranasal administration allowed to increase the residence time of RNAase in blood up to 8 hours at the account of its gradual absorption from the administration site and the preparation availability increased more than 2-fold. The results provided the basis for recommending the intranasal route of bacterial RNAase administration for use in further investigation of RNAase antiviral activity.
Shneĭder
M A
MA
Shtil'bans
E B
EB
Kuprianov-Ashin
E G
EG
Potselueva
L A
LA
Zaikonnikova
I V
IV
Kurinenko
B M
BM
D000190:Actinomyces / Q000201:enzymology*; D000281:Administration, Intranasal; D000818:Animals; D000998:Antiviral Agents; D001682:Biological Availability; D002642:Chick Embryo; D004353:Drug Evaluation, Preclinical; D009980:Influenza A virus; D009981:Influenza B virus; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control; D010919:Placebos; D012259:Ribonuclease, Pancreatic / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012260:Ribonucleases / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000998:Antiviral Agents; D010919:Placebos; D012260:Ribonucleases; D012259:Ribonuclease, Pancreatic
Protivogrippoznoe deĭstvie bakterial'noĭ RNKazy v éksperimente i farmakokineticheskoe obosnovanie sposoba vvedeniia ee v organizm.